No Data
No Data
Maxim Group Maintains Lexaria Bioscience(LEXX.US) With Buy Rating, Maintains Target Price $12
Maxim Group analyst Michael Okunewitch maintains $Lexaria Bioscience(LEXX.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 32
Express News | HC Wainwright & Co. Reiterates Buy on Lexaria Bioscience, Maintains $10 Price Target
H.C. Wainwright Maintains Lexaria Bioscience(LEXX.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright analyst Yi Chen maintains $Lexaria Bioscience(LEXX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 27.4%
Buy Rating on Lexaria Bioscience Fueled by Promising DehydraTECH Advances in Diabetes Drug Development
Lexaria Bioscience Third Quarter 2024 Earnings: Misses Expectations
Express News | Lexaria Bioscience Corp - Dehydratech Appears to Be Working With Semaglutide Both With and Without Snac Technology
No Data